Rhythm Pharmaceuticals Acquires Xinvento, A Netherlands-based Biotech Company Focused On Developing Therapies For Congenital Hyperinsulinism For $5M Upfront
According to the terms of the acquisition agreement, Rhythm B.V. will purchase 100 percent of Xinvento’s fully-diluted equity for an upfront payment of $5 million (subject to customary adjustments) with an
